Aclaris Therapeutics Inc (FRA:8AT)
€ 0.941 0.0414 (4.6%) Market Cap: 67.77 Mil Enterprise Value: -41.80 Mil PE Ratio: 0 PB Ratio: 0.52 GF Score: 58/100

Aclaris Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 08:30PM GMT
Release Date Price: €11.85
Unidentified Participant

All right. Welcome, everyone. The last session of day two 2023 Jefferies Healthcare Conference. We saved the best for the last. So next, presenting company is Aclaris. And with us on the stage is the CEO, Doug; and the CMO, Gail. Welcome.

Doug Manion
Aclaris Therapeutics, Inc. - CEO

Thank you for having us.

Questions & Answers

Unidentified Participant

Awesome. And all right. So maybe just for the people new to the story or already know Aclaris a little bit, what is your updated activated pitch for us?

Doug Manion
Aclaris Therapeutics, Inc. - CEO

And so, I like to say that we're currently version 2.0 of Aclaris. So version 1.0 is a speck derm company that was started by my predecessor, Neal Walker; and Kevin, our CFO's predecessor, Frank Ruffo, about 10 years ago. In the mid-2010s, they made it an extremely good decision to begin to work with a company out of St. Louis called Confluence.

And Confluence is populated by a bunch of really, really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot